Abstract 1584: Epidemiology of Hemorrhagic and Gastrointestinal Adverse Effects of Low-dose Aspirin for Primary Prevention of Atherosclerotic Events in Type 2 Diabetic Patients: Insights From JPAD Trial

Takeshi Morimoto(Hyogo Medical University), Yoshihiko Saito(National Archives and Records Administration), Hisao Ogawa(Kumamoto University Hospital), Hideaki Jinnouchi, Masako Waki(Shizuoka City Hospital), Masafumi Nakayama(Kumamoto University), Seigo Sugiyama(Diabetes Care Center), Shiro Uemura(Nara Medical University Hospital), Naofumi Doi(Nara Medical University), Masao Kanauchi(Nara Medical University), Takahiro Kawano, Hirofumi Soejima(Kumamoto Health Science University)

Circulation

November 3, 2009

Cited by 1

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

|New England Journal of Medicine|2017|9.1k

Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.

|Circulation|1994|1.3k

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

|The Lancet|2017|1.3k

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

|The Lancet|2017|881

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI

|JAMA|2019|848